Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Beneficient filings on SEC EDGAR ↗
Beneficient received a deficiency notice from Nasdaq on November 5, 2026, because its market value of listed securities (MVLS) fell below the $35 million minimum requirement for 30 consecutive business days. The company has until May 4, 2027, to regain compliance by maintaining an MVLS of at least $35 million for at least ten consecutive business days. The notice has no immediate effect on the listing of the company's Class A common stock (BENF) or warrants (BENFW).
Beneficient shareholders approved the issuance of Class A Common Stock to YA II PN, Ltd. (Yorkville) under an Amended and Restated Standby Equity Purchase Agreement (A&R SEPA). The approval satisfies Nasdaq Listing Rule 5635(d), allowing the company to issue shares representing more than 20% of its outstanding common stock upon the conversion of $4.0 million in promissory notes.
Beneficient announced the upcoming launch of AltLens, a technology-enabled alternative asset portfolio analytics and risk platform designed for family offices and small institutional investors. The platform, scheduled to go live in Q4 2026, provides institutional-level risk modeling, stress-testing, and allocation analysis based on historical private market data. This launch aims to capture growing demand for sophisticated oversight tools as global alternative assets under management are projected to reach $29 trillion by 2029.
Beneficient entered into subscription agreements with three of its executives and directors for the private placement of 33,019 shares of Class A common stock. The shares were sold at a price of $1.06 per share to CEO James G. Silk, Chief Fiduciary Officer Derek L. Fletcher, and Director Peter T. Cangany, Jr.
Counterparty
Peter T. Cangany, Jr., Derek L. Fletcher, and James G. Silk